Last week a trial was held before the International Trade Commission (ITC) in the trade secret case brought by Allergan and Medytox against Daewoong and Evolus. Allergan and Medytox filed a complaint with the ITC on January 30, 2019, seeking to block importation of Jeuveau® (prabotulinumtoxinA-xvfs), Evolus’s follow-on biologic to Allergan’s Botox® (onabotulinumtoxinA injection). Daewoong manufactures Jeuveau® in South Korea. Allergan and Medytox alleged that Daewoong misappropriated Medytox’s trade secrets related to the bacterial strain and manufacturing process for Medytox’s botulinumn neurotoxin products. The four-day trial wrapped up on Friday, February 7. The Administrative Law Judge’s Final Initial Determination is due on June 5, 2020, with a target date of October 6, 2020 for the Commission’s final decision.
According to Evolus, Jeuveau® is a “proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.” Evolus received FDA approval for Jeuveau® on February 1, 2019, and began shipment to customers in the United States in May 2019.
We will continue to monitor developments in this case.
The post ITC Trial Wraps Up on Botox Trade Secret Case appeared first on Big Molecule Watch.